New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
08:35 EDTSGENSeattle Genetics presents 'encouraging' activity from ADCETRIS phase 2 trial
Seattle Genetics announced updated results from a phase 2 clinical trial of ADCETRIS in diffuse large B-cell lymphoma and other B-cell non-Hodgkin lymphomas. The data, which demonstrated an "encouraging" activity and tolerability profile in the relapsed and refractory setting was presented. Interim data from an ongoing phase 2 clinical trial were reported from 50 patients with DLBCL and 18 patients with other B-cell lymphomas. Among the DLBCL patients, the median age was 63 years, 74% were refractory to frontline therapy and 82% were refractory to their most recent prior therapy. Patients were treated with single-agent ADCETRIS every three weeks. The trial was designed to assess the antitumor activity, duration of response and safety profile of ADCETRIS in these patients. Of the 50 patients with DLBCL, 42% achieved an objective response, including 16% complete remissions and 26% partial remissions. At the time of data analysis, the median duration of response for DLBCL was 5.8 months. For DLBCL patients who achieved a complete remission, the median duration of response was 11.5 months.
News For SGEN From The Last 14 Days
Check below for free stories on SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTSGENPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 8, 2014
09:03 EDTSGENSeattle Genetics to receive milestone payments from Takeda on Adcetris
Subscribe for More Information
07:35 EDTSGENNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use